Document detail
ID

oai:pubmedcentral.nih.gov:1021...

Author
Thongkum, Weeraya Klayprasert, Puttaporn Semakul, Natthawat Jakmunee, Jaroon Kasinrerk, Watchara Setshedi, Mpho Sayed, Yasien Tayapiwatana, Chatchai
Langue
en
Editor

American Chemical Society

Category

ACS Omega

Year

2023

listing date

9/22/2023

Keywords
pr c-sa hiv-1 hiv biosensor
Metrics

Abstract

[Image: see text] Human immunodeficiency virus (HIV) causing acquired immune deficiency syndrome (AIDS) is still a global issue.

Long-term drug treatment and nonadherence to medication increase the spread of drug-resistant HIV strains.

Therefore, the identification of new lead compounds is being investigated and is highly desirable.

Nevertheless, a process generally necessitates a significant budget and human resources.

In this study, a simple biosensor platform for semi-quantification and verification of the potency of HIV protease inhibitors (PIs) based on electrochemically detecting the cleavage activity of the HIV-1 subtype C-PR (C-SA HIV-1 PR) was proposed.

An electrochemical biosensor was fabricated by immobilizing His6-matrix-capsid (H(6)MA-CA) on the electrode surface via the chelation to Ni(2+)-nitrilotriacetic acid (NTA) functionalized GO.

The functional groups and the characteristics of modified screen-printed carbon electrodes (SPCE) were characterized by Fourier transform infrared (FTIR) spectroscopy, scanning electron microscopy (SEM), and energy-dispersive X-ray spectroscopy (EDS).

C-SA HIV-1 PR activity and the effect of PIs were validated by recording changes in electrical current signals of the ferri/ferrocyanide redox probe.

The detection of PIs, i.e., lopinavir (LPV) and indinavir (IDV), toward the HIV protease was confirmed by the decrease in the current signals in a dose-dependent manner.

In addition, our developed biosensor demonstrates the ability to distinguish the potency of two PIs to inhibit C-SA HIV-1 PR activities.

We anticipated that this low-cost electrochemical biosensor would increase the efficiency of the lead compound screening process and accelerate the discovery and development of new HIV drugs.

Thongkum, Weeraya,Klayprasert, Puttaporn,Semakul, Natthawat,Jakmunee, Jaroon,Kasinrerk, Watchara,Setshedi, Mpho,Sayed, Yasien,Tayapiwatana, Chatchai, 2023, Semi-quantification and Potency Verification of the HIV Protease Inhibitor Based on the Matrix-Capsid Protein Immobilized Nickel (II)/NTA-Tol/Graphene Oxide/SPCE Electrochemical Biosensor, American Chemical Society

Document

Open Open

Share

Source

Articles recommended by ES/IODE AI

Comparison between Dual-Energy CT and Quantitative Susceptibility Mapping in Assessing Brain Iron Deposition in Parkinson Disease
nigra substantia healthy depositions p < 05 nucleus brain susceptibility ct bilateral dual-energy iron quantitative mapping values magnetic globus pallidus
Integration of human papillomavirus associated anal cancer screening into HIV care and treatment program in Pakistan: perceptions of policymakers, managers, and care providers
hpv hiv msm transgender women anal cancer screening integration pakistan system managers pakistan informants anal screening cancer lack healthcare hiv